Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Tennessee Oncology

Neither a doctor nor a teaching hospital

Research payments

$19,627,456

727 payments

Through program year 2025, Tennessee Oncology is reported as receiving $19,627,456 in research payments, across 727 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,714,805 58
2024 Research $1,222,816 46
2023 Research $535,538 23
2022 Research $1,621,927 51
2021 Research $5,313,261 231
2020 Research $6,134,021 115
2019 Research $3,085,087 203

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $7,553,782 45 payments
  2. Merck Sharp & Dohme Corporation $4,196,993 72 payments
  3. BeiGene, Ltd. $2,839,842 89 payments
  4. Pfizer Inc. $1,736,492 32 payments
  5. TESARO, Inc. $656,794 12 payments
  6. Sanofi US Services Inc. $530,372 8 payments
  7. Incyte Corporation $435,101 236 payments
  8. AstraZeneca Pharmaceuticals LP $406,952 32 payments
  9. Boehringer Ingelheim International GmbH $354,285 101 payments
  10. Amgen Inc. $309,547 13 payments
Studies the money was for Research payments · program years 2019–2025
  1. Ribociclib Standard Endocrine Therapy in Patients With HR Her2 Early BC at High Amp Intermediate Risk for Recurrence $5,170,003 6 payments
  2. A Phase 1, Dose-Escalation and Expansion Trial of PT2977, A HIF-2a Inhibitor, In Patients with Advanced Solid Tumors $1,735,321 32 payments
  3. Enzalutamide Mdv3100 Plus Everolimus in Men With Metastatic Prostate Cancer and Previous Treatment With Docetaxel A Phase I Study With An MTD Expansion Cohort $1,461,004 2 payments
  4. A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma $1,199,051 43 payments
  5. An Open-label, Multi-center, Monotherapy, Long-term Extension Study of Zanubrutinib (BGB-3111) in Patients with B-cell Malignancies $939,600 11 payments
  6. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib With Enzalutamide in Metastatic Castrationresistant Prostate Cancer $936,817 20 payments
  7. A Phase 1, Dose-Escalation and Expansion Trial of PT2977, A HIF-2a Inhibitor, In Patients with Advanced Solid Tumors $808,181 1 payment
  8. A Phase 3 Randomized Doubleblind Placebocontrolled Study of Talazoparib in Combination With Physicians Choice of Enzalutamide Or Abiraterone Acetateprednisone in Metastatic Castrationresistant Prostate Cancer With Dna Damage Repair Deficiencies $799,675 12 payments
  9. A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Intolerant of Prior Treatment with Ibrutinib $669,487 13 payments
  10. A Phase I,II open-label study of the safety, tolerability and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, checkpoint inhibitor relapsed tumors $661,428 23 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record